Clearance Summary
InVision Precision Cardiac Amyloid received FDA 510(k) clearance under submission number K243866, sponsored by InVision Medical Technology Corporation. The device was reviewed via the Traditional premarket notification pathway and assigned to the Cardiovascular review panel. The statutory decision date of record is 2025-05-21.
- Submission: K243866
- Applicant / Sponsor: InVision Medical Technology Corporation
- Clearance pathway: Traditional
- Review panel: Cardiovascular
- Device class: Class II
- Regulation citation: 21 CFR 870.2200
- Decision date: 2025-05-21
Classification & Regulation
This clearance is catalogued under FDA product code SDJ and 21 CFR 870.2200, within the Cardiovascular review panel as a Class II device.